The KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer and thyroid cancer. The existence of KRAS mutations is often associated with a prognostic marker of drug response. For example, the KRAS mutation is considered a strong prognostic marker for drug response to tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related to drug response to Cetuximab (Erbitux) or Panitumumab (Vectibix) used for colon cancer therapy. Therefore, KRAS mutation testing is necessary to determine drug resistance in patients with colorectal or lung cancer and will be useful for anticancer therapies.
PANAMutyper™ R KRAS
To detect KRAS mutations and determine their response to various treatments in colon cancer.
Cat. No. PNAR-1001
Other products
virotype PEDV/TGEV/PDCoV Primers/Probes (480 reactions)
Primers and probes for the amplification and detection by multiplex...
EZ-10 Spin Column Animal Genomic DNA Miniprep Kit – BS427 / BS628
EZ-10 Spin Column Animal Genomic DNA Miniprep Kit: The EZ-10...
MI vortex mixer with LED digital display – FourEs (MI0101002D)
Mixer with separate LED displays for speed and time. This,...
Biospin Total RNA Extraction Kit-100T-PCR/RT-PCR KIT(BSC63M1)
Effective kit to isolate total RNA from different sources. Simple,...